1.59
+0.02(+1.27%)
Currency In USD
| Previous Close | 1.57 |
| Open | 1.56 |
| Day High | 1.61 |
| Day Low | 1.54 |
| 52-Week High | 4.08 |
| 52-Week Low | 1.45 |
| Volume | 1.92M |
| Average Volume | 4.28M |
| Market Cap | 421.93M |
| PE | -19.87 |
| EPS | -0.08 |
| Moving Average 50 Days | 2.33 |
| Moving Average 200 Days | 2.72 |
| Change | 0.02 |
If you invested $1000 in Akebia Therapeutics, Inc. (AKBA) 10 years ago, it would be worth $160.93 as of December 04, 2025 at a share price of $1.59. Whereas If you bought $1000 worth of Akebia Therapeutics, Inc. (AKBA) shares 5 years ago, it would be worth $516.23 as of December 04, 2025 at a share price of $1.59.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Akebia Announces Establishment of Rare Kidney Disease Pipeline
GlobeNewswire Inc.
Dec 01, 2025 12:00 PM GMT
Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2 trial of Praliciguat, an sGC stim
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 24, 2025 1:00 PM GMT
CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that members of its executive team
Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs
GlobeNewswire Inc.
Nov 06, 2025 11:30 PM GMT
Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people